Iranian Drug Becoming the New Hope for a Coronavirus Treatment

Wednesday, March 11, 2020 - 13:26

The Health Ministry spokesman Kianoush Jahanpour has announced on relative improvement of patients with known COVID-19 through using Iranian drug.

According to an ISCA report, Kianoush Jahanpour approved that Actemra could cause relative improvement of a patient with severe COVID-19 in Isfahan and stated that this has been the first case trial of Iranian biosimilar drug "Tocilizumab".

He noted that after using the drug, the disease symptoms fairly decreased but it is too soon for the treatment to be judged.

Jahanpour declared that within the coming days, the trial will be done for other patients as well and in condition of having effective results, it will be placed in the list of the country's Drug List.

As he emphasized, due to the localization of the technology, the drug mass production and its market availability would take at least 3 weeks.

It has been reported recently that a drug used to treat inflammation in arthritis patients, Actemra, could be the answer to coronavirus cure.

Actemra, known generically as tocilizumab, is a biologic drug approved in 2010 in the United States for rheumatoid arthritis (RA). The drug contains high Interleukin 6 (IL-6) protein levels that drive some inflammatory diseases.

Gelare Khademvesal


Popular News

Latest News